Sergeeva
Anna Sergeeva, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20110293620 | Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease - The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-I in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided. | 12-01-2011 |
Olga Rafaelevna Sergeeva, Moscow RU
Patent application number | Description | Published |
---|---|---|
20080210595 | Light Oil Fuel - The invention relates to oil refining, more particularly to a composition of a light fuel oil for use in medium-speed diesel engines of marine power units. The inventive light fuel oil comprises, in % by wt.: black oil—(4-10), tar—(2-10), light catalytic cracking gas oil—(10-30), heavy catalytic cracking gas oil—(5-10), a straight-run diesel fuel—(8-10), a viscosity breaking residuum of a heavy oil fraction—the rest. The selected component ratio will enable to improve the fuel stability in transportation and storage, expand the range of available fuels and increase the production volumes of quality fuels, while rationally using poor-quality products readily available at refineries. | 09-04-2008 |
Svetlana Alexandrovna Sergeeva, Moscow RU
Patent application number | Description | Published |
---|---|---|
20120251584 | Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system - The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. | 10-04-2012 |
20130017202 | Pharmaceutical compositions and methods of treatmentAANM Epshtein; Oleg IliichAACI MoscowAACO RUAAGP Epshtein; Oleg Iliich Moscow RUAANM Sergeeva; Svetlana AlexandrovnaAACI MoscowAACO RUAAGP Sergeeva; Svetlana Alexandrovna Moscow RUAANM Dolgovyh; Liudmila FyodorovnaAACI ChelyabinskAACO RUAAGP Dolgovyh; Liudmila Fyodorovna Chelyabinsk RUAANM Kheyfets; Irina AnatolievnaAACI DolgoprudnyAACO RUAAGP Kheyfets; Irina Anatolievna Dolgoprudny RUAANM Dugina; Julia LeonidovnaAACI MoscowAACO RUAAGP Dugina; Julia Leonidovna Moscow RUAANM Zabolotneva; Julia AlexandrovnaAACI MoscowAACO RUAAGP Zabolotneva; Julia Alexandrovna Moscow RUAANM Tarasov; Sergey AlexandrovichAACI GolitsynoAACO RUAAGP Tarasov; Sergey Alexandrovich Golitsyno RU - The present invention provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and use in the treatment of obesity and related metabolic disorders. The present invention further provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and activated potentiated form of an antibody to protein S-100 for use in the treatment of addiction to psychoactive substances. | 01-17-2013 |
20130189707 | METHOD OF DETERMINATION OF AUTOANTIBODY LEVEL BY MEANS OF ENZYME IMMUNOASSAY - The method for quantitative determination of the level of natural autoantibodies in human biological fluids, when as a solid phase of physical sorption is used the solid phase of physical sorption, coated with streptavidin, and the solid phase of physical sorption is treated with preliminary biotinylated antigen and blocking agent for closing the sites of nonspecific binding at the solid phase of physical sorption, for which purpose are used proteins, biotinylated according to standard procedure. As the conjugate-containing solution are used enzyme-labeled monoclonal and polyclonal antibodies, which react with one or all isotypes of human immunoglobulins. In addition, the tested biological fluid is preliminary diluted in a buffer, containing proteins which are used for closing the sites of nonspecific binding at solid phase of physical sorption, and also substances protecting natural autoantibodies from destruction during heat treatment, and subjected to heat treatment. For each tested specimen of biological fluid, a control solid phase of physical sorption is used, and the number of natural autoantibodies is determined with the use of a calibration curve which is plotted using monoclonal or polyclonal antibodies to antigen. | 07-25-2013 |